Home About Products Partners Contact

Disclosures

Regulatory & Registration Details Read Disclaimer SID | SAI | KIM & Brokerage Details SEBI Circulars Important Links Code of Conduct Risk Factors Terms and Conditions Talk to Us

SID | SAI | KIM & Brokerage Details

Commission disclosures as per SEBI Circular SEBI/IMD/CIR No. 4/168230/09 — commission, brokerage and trail from Mutual Funds.

Trail brokerage ranges by mutual fund scheme category
Mutual Fund SchemesTrail Brokerage
Equity Schemes
Equity Funds0.20% to 1.60%
ELSS Funds0.50% to 1.45%
Hybrid Schemes
Asset Allocation Funds0.70% to 1.50%
Arbitrage Funds0.40% to 0.70%
Hybrid Funds0.20% to 1.30%
Debt Schemes
Gilt Funds0.30% to 1.00%
Income & Bond Funds0.40% to 1.20%
Short Term Funds0.40% to 0.80%
Liquid & Debt Funds0.05% to 0.35%
Other Schemes
Index Funds0.10% to 0.70%
  • All transactions executed through SHRI MASUN Financial Services are “execution only” transactions and no advice is given.
  • This is on a best effort basis; details of scheme level commission on Mutual Funds would be produced on demand.
  • With effect from 1st November 2011, SHRI MASUN Financial Services has “opted-out” for transaction charge as per the SEBI Circular No. CIR/IMD/DF/13/2011 dated 22nd August 2011.

Scheme documents - SID | SAI | KIM

Every mutual fund scheme is governed by its Scheme Information Document (SID), Statement of Additional Information (SAI) and Key Information Memorandum (KIM). These set out the scheme’s objective, asset allocation, risk factors, expense ratio and exit load, and they are the documents that legally govern your investment — not any material published here.

The current SID, SAI and KIM for each scheme are published by the respective Asset Management Company and are available free of charge:

  • On the website of the AMC whose scheme you are invested in, or hold with us.
  • On the AMFI India website, which aggregates scheme information across all AMCs — amfiindia.com.
  • On request from us — we will send the current SID, SAI and KIM for any scheme in your portfolio.